Five Centers of Nausea. Linda Tavel, MD Program Medical Director VistaCare Hospice

Size: px
Start display at page:

Download "Five Centers of Nausea. Linda Tavel, MD Program Medical Director VistaCare Hospice"

Transcription

1 Five Centers of Nausea Linda Tavel, MD Program Medical Director VistaCare Hospice

2 Objectives Prevalence of nausea and vomiting Anatomic and physiologic paths to nausea Evaluation of nausea Treatment of nausea Case Studies

3 Nausea Subjective sensation Often multifactorial Other symptoms occur: Sweating Salivation Tachycardia Most unpleasant of symptoms

4 It s great to be a cow. Vomiting absent in rats, rabbits, cows Rare in horses, ungulates

5 Vomiting Matter is ejected from GI tract Aka emesis (Gr.( Emein and Indo. wem ) wem Usually accompanied by nausea

6 What is vomiting? Three different actions: Salivation (from parasympathetic nervous system) Retroperistalsis,, from mid small intestine, pushing contents from digestive tract, into stomach, through relaxed pyloric sphincter Glottis closes, reducing aspiration risk Increase in abdominal pressure as muscles contract, propel stomach contents into esophagus, through relaxed lower esophageal sphincter

7 Prevalence Cancer 62% terminally ill patients--at least 40% last 6 weeks life Common in end stage heart disease Frequently seen in HIV/AIDs Liver failure Renal failure

8 Prevalence Chemotherapy Radiation therapy Opiates Medications Anorexia/cachexia syndrome

9 Causes Can be determined in most patients Up to 75% Medications Metabolic Infections Gastric slowing Constipation Always look for reversible/treatable causes first

10 Five centers. Important to determine which etiologies are involved Since multifactorial, may require more than one medication/strategy But, shotgunning not optimal Treatment aimed at underlying cause Assessment vital!

11 Assessment of Nausea and Vomiting Nausea intensity (0-10), duration, description Aggravating or activating factors QUality of life impact of N,V Symptoms accompanying N,V Emetic episodes per 24 hrs (+ timing) Alleviating factors Dahlin,, Management of Symptoms Other than Pain 2006

12 Pathophysiology of nausea / vomiting Chemoreceptor Trigger Zone (CTZ) Vomiting center Neurotransmitters Serotonin Dopamine Acetylcholine Histamine Neurokinin Cortex Vestibular apparatus GI tract

13 Where are the receptors?

14 Cortical causes of nausea Meningitis Increased intracranial pressure Anxiety (conditioning) Visual stimulus Olfactory stimulus Pain Cerebral edema due to metastases

15 Treatment of cortical pathway GABA neurotransmitter Benzodiazepines Lorazepam mg po q 4 hrs Clonazepam--longer longer acting 0.25 mg po q 12 hrs scheduled, increase q 3 days, 4 mg/d max Alprazolam--rapid rapid onset, burns off quickly mg po (panic) Treat the underlying cause!

16 Case study 41 y/o female with metastatic rectal adenocarcinoma,, multiple admissions to hospital with intractable nausea and vomiting. Resolves somewhat with hydration. Ondansetron 8 mg q 8 hrs is ineffective. Not currently receiving chemo. Patient also with fungating wound of perineum. Significant odor. Patient reports with peri- care and dressing changes the nausea worsens significantly.

17 Pathophysiology of nausea / vomiting Chemoreceptor Trigger Zone (CTZ) Vomiting center Neurotransmitters Serotonin Dopamine Acetylcholine Histamine Neurokinin Cortex Vestibular apparatus GI tract

18 Case 1 continued How would you treat her? What are the possible causes of her nausea and vomiting? Topical flagyl to wound reduced odor Lorazepam 0.5 mg po q 4 hours prn anxiety, administered prior to dressing change Dietician consult for strategies to maintain hydration

19

20 Vestibular causes of nausea Tumor at base of skull Medications Motion sickness Conflicting signals visual vs. other input

21 What are the receptors?

22 Treatment of Vestibular pathway Receptors are muscarinic and histaminergic Work through decreasing excitability of labyrinths and block conduction of vestibular-cerebellar pathway Antihistamines are sedating Anticholinergics are exciting!!! (primarily due to all those side effects) Agitation, urinary retention, constipation

23 Medications Antihistamines Diphenydramine 25-50mg 50mg po/sc/pr q 4 hr prn Hydroxyzine (Atarax)(Atarax Promethazine (Phenergan) Weak dopamine antagonist Meclizine (Antivert)(Antivert

24 Medications Anticholinergics antimuscarinics Hyoscyamine (Levsin) mg po/sl q 4 hrs prn or scheduled Atropine 1% ophthalmic drops drops sl q hrs prn Scopolamine transdermal patches 1 patch q 72 hrs Glycopyrrolate (Robinul) mg po/sc q 8 hrs

25

26 Chemoreceptor Trigger Zone Area postrema on floor of 4th ventricle Lies outside blood-brain brain barrier Medications: digoxin opiates Clonidine anticonvulsants antiretrovirals Antibiotics NSAIDs Metabolic: hypercalcemia,, uremia

27 Chemoreceptor Trigger Zone Chemotherapeutic agents Serotonin released by dying cells Immediate emetogenicity versus delayed Bacterial toxins Mechanoreceptors from increased ICP Following radiation therapy Whole body, mediastinal,, upper abdomen

28 Emetogenicity

29 Emetogenicity

30 Anatomy of CTZ

31 What are the receptors?

32 Treatment for CTZ nausea Dopamine antagonists Haloperidol 0.5 mg q hrs prn, titrate up in dose Pills, liquid, may give SQ Prochlorperazine (Compazine) ) mg po/pr q 4 hr prn Metoclopramide (Reglan)--also also 5HT4, at higher doses, 5HT3 More commonly for prokinetic action in gut 5-10 mg po/sc/pr QID, up to 100 mg/d (GI)

33 Treatment for CTZ nausea Setrons --Serotonin Setrons -- Serotonin antagonists Ondansetron (Zofran) po or IV 4-88 mg po q hrs/single IV dose (4-32mg) Granisetron (Kytril) mg po daily 4-32 mg IV once Dolasetron (Anzemet) Palonosetron (Aloxi)(Aloxi

34 Treatment for CTZ nausea Setrons --Serotonin Setrons -- Serotonin antagonists Prophylactically or routinely scheduled Very expensive!!!! Kytril or Zofran about $90 per day Others much more.

35 Treatment for CTZ nausea Substance P/NeuroKinin-1 1 receptor antagonist Aprepitant (Emend) Only for chemotherapy induced nausea 3 day regimen, po $300/3 days For delayed nausea as well T1/2 about 3 days

36 GI causes for nausea Peripheral Teeth to tail!!!!!! Biliary obstruction Constipation Gastric distension Gastroparesis Liver disease

37 GI causes for nausea Bowel obstruction Partial or complete Pharyngeal lesions Esophagitis Mucositis Visceral Pain

38 What are the receptors?

39 Treatment of GI pathway Assess fully!!! Treat the underlying condition Constipation, esophagitis,, mucositis

40 Treatment of GI pathway Prokinetic agents For gastric emptying Metoclopramide (Reglan) 5-20 mg po/pr/sq q 6 hrs Antidopaminergic at higher doses Dystonic reactions with higher doses and if combined with 5HT3 receptor antagonists, antidepressants, antipsychotics

41 Treatment of GI pathway AntiAcid agents Proton pump inhibitors Omperazole (OTC) mg/d po Lansoprazole,, mg/d Pantaprazole 40 mg/d Esmeprazole mg/d

42 Vomiting Center The final common pathway!!! Lateral medullary reticular formation in the pons Multiple receptors Histaminic, muscarinic cholinergic, 5HT2

43 What are the receptors?

44 Treatment of Vomiting Center Treat underlying cause Antihistamines Diphenydramine 25-50mg 50mg po/sc/pr q 4 hr prn Hydroxyzine (Atarax)(Atarax Promethazine (Phenergan) Weak dopamine antagonist Meclizine (Antivert)(Antivert

45 Treatment of Vomiting Center Anticholinergics antimuscarinics Hyoscyamine (Levsin) mg po/sl q 4 hrs prn or scheduled Atropine 1% ophthalmic drops drops sl q 2-44 hrs prn Scopolamine transdermal patches 1 patch q 72 hrs Glycopyrrolate (Robinul) mg po/sc q 8 hrs

46 Treatment of Vomiting Center Multireceptor antagonist: Olanzapine (Zyprexa) Antagonist D2, H1, 5HT2, Muscarinic cholinergic 5-20 mg po daily 2.5 mg SC up to 4 times daily This is off label use, but gaining favor

47 Treatment of Vomiting Center Multireceptor antagonist: Mirtazapine (Remeron) Antagonist for 5HT3, 5HT4, H1 15mg po BID Often used for anorexia off label

48 Miscellaneous treatments of nausea, vomiting Steroids Adjunctive therapy Emesis prevention in chemotherapy and radiation therapy Helpful in edema from brain metastases Also used in bowel obstruction We don t t know how steroids work..eduardo.. Bruera,MD Feb 25, 2008

49 Miscellaneous treatments of nausea, vomiting Steroids continued Dexamethasone mg po/sc 1-21 times daily Prednisone mg po daily Anti-inflammatory, inflammatory, promotes sense of well being, increases appetite

50 Miscellaneous treatments of nausea, vomiting Cannabinoid receptor antagonists Tetrahydrocannabinol (Marinol)/(Dronabinol) Indication chemotherapy related n,v HIV anorexia 2.5 mg BID po up to 20mg/day Euphoria, dysphoria 30 day supply= $284. 5HT3/metoclopramide/dexamethasone more in favor for chemotx related n,v

51 Alternative therapies Accupressure P6 best known Hypnosis Ginger Ginger ale, ginger tea, ginger candies Ginger root more effective than placebo mg ginger root qid Aromatherapy not ideal due to conditioning

52 Remember Case 1? 41 y/o with metastatic rectal cancer, Fungating rectal wound Nausea controlled fairly well with topical antibiotics and anxiolytic therapy. Continued to have low grade nausea. Why might she have nausea?

53 Where are the receptors?

54 What would you add to regimen? What tests? What interventions?

55 Pathophysiology of nausea / vomiting Chemoreceptor Trigger Zone (CTZ) Vomiting center Neurotransmitters Serotonin Dopamine Acetylcholine Histamine Neurokinin Cortex Vestibular apparatus GI tract

56 Malignant Bowel Obstruction Symptom management NG tubes occasional helpful short term Opioids for pain Anticholinergics to reduce secretions and reduce peristalsis (levsin)(levsin ( Haloperidol for nausea (concern about metoclopramide in complete obstn) Dexamethasone to reduce inflammation and?edema

57 Malignant Bowel Obstruction Octreotide Somatostatin analog Reduces gastrointestinal motility Reduces gastric, pancreatic, small intestine secretions Improves water and electrolyte absorption micrograms BID-TID SC/IV

58 Summary Five Pathways in nausea, vomiting Multiple receptors Multiple mechanisms Good assessment Treat underlying condition Add layers of medications I.e. dopaminergic,, steroid, 5HT3 Hydration

59 Case 2 UNIPAC-Selena Selena 58 y/o widow with advanced breast cancer, PPS 40%. S/P chemotherapy and radiation to chest wall, right arm, hip. Principal complaint pain in right arm and severe nausea. Meds: piroxicam (Fedlene)(Fedlene ) 20mg daily, morphine extended release 30 mg BID, theophylline slow release 300 mg BID

60 Where are the receptors?

61 Case 2 continued Nausea has been mild, chronic, increased over last 2 days when MD changed Selena from Tylenol #3 (codeine 30 mg) 1 q 4 hr prn to Morphine ER 30 mg BID. No BM for 4 days, increasing nausea at mealtime Piroxicam 20 mg for OA, now for bony mets Bronchitis,, but no hx asthma?

62 Case 2 continued What would you do? What medication changes would you make? Discontinue piroxicam Discontinue theophylline Change Morphine ER back to shorter acting opiate (oxycodone) Laxative

63 Case 2 continued Oxycodone, antacids, laxatives, and albuterol inhaler are effective Over time, escalating doses of oxycodone ER Nauseated much of the day and vomiting after eating, still with regular BMs Increased arm pain, weakness, nausea

64 Case 2 continued What medications or treatments would you offer now? Dexamethasone 4 mg Metaclopramide Haloperidol

65 Case 2 After the interventions aforementioned, Selena improves for awhile Selena experiences increasing confusion and sedation At this point, what tests or interventions?

66 Bibliography Module 3p Symptoms-Nausea/Vomiting EPEC- Oncology National Cancer Institute to order copy Storey, P. Nausea and Vomiting. UNIPAC Four: Management of Selected Non-pain Symptoms in the Terminally Ill. American Academy of Hospice and Palliative Medicine Twycross,, R Wilcock,, A. Hospice and Palliative Care Formulary USA. Palliativedrugs.com, Ltd. 2006

67 Bibliography Dahlin,, C Lynch, M et al. Management of Symptoms Other Than Pain. Anesthesiology Clin N Am 2006;(24): Montagnini,, M Moat, M. Non-Pain Symptom Management in Palliative Care. 2004;6(2): Wood, G Shega,, J Lynch, B Von Roenn,, J. Management of Intractable Nausea and Vomiting in Patients at the End of Life. JAMA. 2007;208(10): Chemotherapy-Related Nausea and Vomiting.Interactive Textbook on Clinical Symptom Research. Accessed 3/4/08

Symptom Management. Thomas McKain, MD, ABFM, ABHPM Medical Director

Symptom Management. Thomas McKain, MD, ABFM, ABHPM Medical Director Symptom Management Nausea & Vomiting Thomas McKain, MD, ABFM, ABHPM Medical Director Mr. Jones has nausea and vomiting. May I initiate Compazine from the Comfort Pak? Objectives 1. Delineate the Differential

More information

Nausea. Assessment & Management. R J Crossno, MD, CMD, FAAFP, FAAHPM. Disclosures

Nausea. Assessment & Management. R J Crossno, MD, CMD, FAAFP, FAAHPM. Disclosures Nausea Assessment & Management R J Crossno, MD, CMD, FAAFP, FAAHPM Disclosures Dr. Crossno discloses his employment as Area Medical Director for VistaCare VistaCare has provided commercial support for

More information

Nausea and Vomiting in Palliative Care

Nausea and Vomiting in Palliative Care Nausea and Vomiting in Palliative Care Definitions Nausea - an unpleasant feeling of the need to vomit Vomiting - the expulsion of gastric contents through the mouth, caused by forceful and sustained contraction

More information

GI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics. Dr. Alia Shatanawi

GI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics. Dr. Alia Shatanawi GI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics Dr. Alia Shatanawi 11-04-2018 Drugs used in Irritable Bowel Syndrome Idiopathic, chronic, relapsing disorder characterized by abdominal discomfort

More information

Managing Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting

Managing Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe

More information

Approach to Nausea & Vomi2ng

Approach to Nausea & Vomi2ng Approach to Nausea & Vomi2ng Med 3 Seminar 2017 Dr. Robin Grant Division of Pallia2ve Medicine robin.grant@nshealth.ca Why nausea and vomi2ng? Pain 80-90+ % Fa2gue / asthenia 75-90% Cons2pa2on 70% Dyspnea

More information

DECONTAMINATION AGENTS and ANTIEMETICS *** This material won t be covered in lecture, but you are responsible for it***

DECONTAMINATION AGENTS and ANTIEMETICS *** This material won t be covered in lecture, but you are responsible for it*** Decontamination and Antiemetics Med 5724 Page 1 of 8 DECONTAMINATION AGENTS and ANTIEMETICS *** This material won t be covered in lecture, but you are responsible for it*** REFERENCES: Katzung (9th ed.)

More information

9/20/2017. Effectively Managing Nausea and Vomiting. Disclosure. Objectives

9/20/2017. Effectively Managing Nausea and Vomiting. Disclosure. Objectives Effectively Managing Nausea and Myra Belgeri, Pharm.D, BCGP, BCPS, FASCP Clinical Pharmacist, Optum Hospice Pharmacy Services October 2017 1 Disclosure I have no relevant financial relationships with manufacturers

More information

A SLP s Guide to Medication Therapy and Management. Sarah Luby, PharmD, BCPS KSHA 2017

A SLP s Guide to Medication Therapy and Management. Sarah Luby, PharmD, BCPS KSHA 2017 A SLP s Guide to Medication Therapy and Management Sarah Luby, PharmD, BCPS KSHA 2017 Objectives Identify the appropriate route of administration for medications and proper formulations for use Understand

More information

Vomiting Approach to diagnosis

Vomiting Approach to diagnosis Vomiting Approach to diagnosis By Dr. Sahar El-Gharabawy Associate professor of internal medicine Hepato-gastroenterology Unit )SMH ) Mansoura University Definitions: Nausea: Feeling "sick to the stomach",

More information

Using Evidence Based Medicine to Ethically Provide End of Life Symptom Control

Using Evidence Based Medicine to Ethically Provide End of Life Symptom Control Using Evidence Based Medicine to Ethically Provide End of Life Symptom Control Erin Zimny, MD Emergency Medicine Hospice and Palliative Medicine Henry Ford Hospital Disclosures I do NOT have any financial

More information

Delirium and Nausea. Delirium - definition. Delirium Incidence. Predisposing Risk Factors for Delirium. Impact. Delirium Types 10/14/2016

Delirium and Nausea. Delirium - definition. Delirium Incidence. Predisposing Risk Factors for Delirium. Impact. Delirium Types 10/14/2016 Delirium - definition Delirium and Nausea Etiologically non-specific global cerebral dysfunction associated with changes in LOC, attention, thinking, perception, memory, psychomotor behavior, emotion and

More information

Nausea & Vomiting. Dr Eve Lyn TAN Liverpool Hospital NSW, AUSTRALIA

Nausea & Vomiting. Dr Eve Lyn TAN Liverpool Hospital NSW, AUSTRALIA Nausea & Vomiting Dr Eve Lyn TAN Liverpool Hospital NSW, AUSTRALIA Prevalence prevalence varies *, systemic review 2007 : overall prevalence : nausea 30%, vomiting 20% in last 1-2 weeks of life : nausea

More information

Part 2: Pain and Symptom Management Nausea and Vomiting

Part 2: Pain and Symptom Management Nausea and Vomiting Part 2: Pain and Symptom Management Nausea and Vomiting Effective Date: February 22, 2017 Key Recommendations Select anti-nausea medication based on the etiology of the nausea and vomiting. Assessment

More information

Clinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:

Clinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date: Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017

Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors

More information

Disclosures 9/17/2018. Best Practices in the Treatment of Nausea and Vomiting

Disclosures 9/17/2018. Best Practices in the Treatment of Nausea and Vomiting Best Practices in the Treatment of Nausea and Vomiting Jennifer Gabbard, MD Wake Forest School of Medicine jgabbard@wakehealth.edu 42 nd Annual Hospice & Palliative Care Conference September 2018 Charlotte,

More information

Chapter 29 - Nausea and Vomiting

Chapter 29 - Nausea and Vomiting Chapter 29 - Nausea and Vomiting Episode Overview: 1) Describe the mechanism of development of a Hypochloremic Metabolic Alkalosis in vomiting 2) List commonly used anti-emetics including their dose and

More information

Nausea and Vomiting. Principles and Practice in End of Life Care November 2018

Nausea and Vomiting. Principles and Practice in End of Life Care November 2018 Nausea and Vomiting Principles and Practice in End of Life Care November 2018 Overview Aims and Objectives Why is managing nausea and vomiting important? Definitions Causes Interventions pharmacological

More information

First a caution. Processes we might NOT try to treat with medications. Processes we might try to treat. Main drug categories.

First a caution. Processes we might NOT try to treat with medications. Processes we might try to treat. Main drug categories. Pharmacological Interventions for dizziness Timothy C. Hain, MD Northwestern University Medical School Chicago, Illinois, USA First a caution Torok N. Old and new in Meniere's disease. Laryngoscope 87:1870-1877,

More information

3/27/2013. Objectives. Psychopharmacology at the End of Life Nicole Thurston, MD

3/27/2013. Objectives. Psychopharmacology at the End of Life Nicole Thurston, MD Psychopharmacology at the End of Life Nicole Thurston, MD Psychiatrist Mountain States Tumor Institute Objectives Describe 2 common psychiatric symptoms that can present at or near end of life. Review

More information

Generic (Brand) Strength & Dosage form Fml Limit Cost per Rx Notes 5-HT3 Antagonists

Generic (Brand) Strength & Dosage form Fml Limit Cost per Rx Notes 5-HT3 Antagonists MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Nausea LAST REVIEW 9/11/2018 THERAPEUTIC CLASS Gastrointestinal Disorders REVIEW HISTORY 12/16, 11/15, 11/07 LOB AFFECTED

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients

Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium Goals and Objectives: Describe

More information

Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients

Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium 1 Goals and Objectives: Describe

More information

Management of Postoperative Nausea and Vomiting in Ambulatory Surgery The Big Little Problem

Management of Postoperative Nausea and Vomiting in Ambulatory Surgery The Big Little Problem Management of Postoperative Nausea and Vomiting in Ambulatory Surgery The Big Little Problem Mary Keyes, MD KEYWORDS Postoperative nausea and vomiting PONV prophylaxis PONV in ambulatory surgery KEY POINTS

More information

SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL

SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL If a patient is believed to be approaching the end of their life, medication should be prescribed in anticipation

More information

Grace Ma and Andrea Weiss FMF 2018

Grace Ma and Andrea Weiss FMF 2018 Grace Ma and Andrea Weiss FMF 2018 Presenter: Grace Ma Relationships with financial sponsors: none Presenter: Andrea Weiss Relationships with financial sponsors: none This program has not received any

More information

Clinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:

Clinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date: Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Neuro Basics SLO Practice (online) Page 1 of 5

Neuro Basics SLO Practice (online) Page 1 of 5 Neuro Basics SLO Practice (online) Page 1 of 5 1) Biogenic amines include ACh, NE, EPI and? a) Melatonin b) Dopamine c) Serotonin d) Histamine e) All of the neurotransmitters listed are biogenic amines.

More information

First a caution. Processes we might NOT try to treat with medications. Processes we might try to treat. Main drug categories.

First a caution. Processes we might NOT try to treat with medications. Processes we might try to treat. Main drug categories. Pharmacological Interventions for dizziness Timothy C. Hain, MD Northwestern University Medical School Chicago, Illinois, USA First a caution Torok N. Old and new in Meniere's disease. Laryngoscope 87:1870-1877,

More information

Somatostatin analogues. Other drugs

Somatostatin analogues. Other drugs Octreotide Somatostatin analogues Lack the adverse effects of antimuscarinic agents Somatostatin decreases the release of gastrin, insulin, glucagon, gastric acid and pancreatic enzymes Also inhibits neurotransmission

More information

ATTUALITÀ NEL CONTROLLO DELL EMESI

ATTUALITÀ NEL CONTROLLO DELL EMESI ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions

More information

We would like to thank you for completing this audit questionnaire which looks at how you manage nausea and vomiting in palliative care patients.

We would like to thank you for completing this audit questionnaire which looks at how you manage nausea and vomiting in palliative care patients. We would like to thank you for completing this audit questionnaire which looks at how you manage nausea and vomiting in palliative care patients. The closing date for responses is 19th December The results

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this

More information

Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients

Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients Done by :Meznah Zaid Al-Mutairi Pharm.D Candidate PNU University College of Pharmacy Introduction Nausea

More information

Pharmacology. Drugs that Affect the Gastrointestinal System

Pharmacology. Drugs that Affect the Gastrointestinal System Pharmacology Drugs that Affect the Gastrointestinal System Topics Peptic Ulcer Disease Constipation Diarrhea Emesis Digestion Peptic Ulcer Disease Factors that Increase Acidity Factors that Protect Against

More information

Inpatient Palliative Medicine Update

Inpatient Palliative Medicine Update Inpatient Palliative Medicine Update David Dupere MD, FRCPC Head, Division of Palliative Medicine Department of Medicine QEII Health Sciences Centre Halifax, Nova Scotia Disclosures Book chapter in Compendium

More information

Syringe driver in Palliative Care

Syringe driver in Palliative Care Syringe driver in Palliative Care Introduction: Syringe drivers are portable, battery operated devices widely used in palliative care to deliver medication as a continuous subcutaneous infusion over 24

More information

Second term/

Second term/ Second term/ 2015-2016 L. 1 Dr Mohammed AL-Zobaidy Learning objectives GIT pharmacology After completing this chapter the student will be able to: Recognise pathophysiological factors implicated in acid-peptic

More information

PRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist

PRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist PRESCRIBING PRACTICE IN DELIRIUM John Warburton Critical Care Pharmacist Learning outcomes Modifiable medication risk factors for delirium An appreciation of contributing factors modifiable with medicines

More information

PAIN. Physiology of pain relating to pain management

PAIN. Physiology of pain relating to pain management PAIN Physiology of pain relating to pain management What is pain? An unpleasant sensory and emotional experience associated with actual or potential tissue damage. (Melzac and Wall) The generation of pain

More information

Introduction & Expectations Learning Objectives Etiology & Pathophysiology of Nausea & Vomiting Pharmacology of Dimenhydrinate...

Introduction & Expectations Learning Objectives Etiology & Pathophysiology of Nausea & Vomiting Pharmacology of Dimenhydrinate... Primary Care Paramedic Dimenhydrinate (Gravol) Certification Learner Package www.lhsc.on.ca/bhp 1 Table of Contents Introduction & Expectations... 4 Learning Objectives... 4 Etiology & Pathophysiology

More information

PAIN MANAGEMENT Person established taking oral morphine or opioid naive.

PAIN MANAGEMENT Person established taking oral morphine or opioid naive. PAIN MANAGEMENT Person established taking oral morphine or opioid naive. Important; it is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member

More information

Nausea and Vomiting Team. Outcome: Nausea and Vomiting. Scope of the Problem. Definition: Nausea

Nausea and Vomiting Team. Outcome: Nausea and Vomiting. Scope of the Problem. Definition: Nausea Nausea and Vomiting: The Continuing Battle to Improve Outcomes Jan Tipton, MSN, RN, AOCN Oncology CNS Medical University of Ohio Toledo, Ohio jtipton@meduohio.edu Nausea and Vomiting Team Jan Tipton, MSN,

More information

PAIN MANAGEMENT Patient established on oral morphine or opioid naive.

PAIN MANAGEMENT Patient established on oral morphine or opioid naive. PAIN MANAGEMENT Patient established on oral morphine or opioid naive. Important; It is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member

More information

Learning Objectives. Delirium. Delirium. Delirium. Terminal Restlessness 3/28/2016

Learning Objectives. Delirium. Delirium. Delirium. Terminal Restlessness 3/28/2016 Terminal Restlessness Dr. Christopher Churchill St. Cloud VA Health Care System EC&R Service Line Director & Medical Director Hospice & Palliative Care March 31, 2016 Learning Objectives Different Terminology

More information

Management of Delirium in Hospice Patients

Management of Delirium in Hospice Patients Presentation Objectives Management of Delirium in Hospice Patients Lynn Williams, BSPharm Clinical Pharmacist Hospice Pharmacy Solutions Identify the clinical features of delirium Understand the underlying

More information

Scott Akin MD FAAFP

Scott Akin MD FAAFP Scott Akin MD FAAFP sakin@emory.edu I have no financial disclosures Outline Review key palliative care articles of 2016 related to pain and symptom management AAHPM PC-FACS (monthly review of literature)

More information

Attach patient label here. Physician Orders ADULT: Palliative Care Plan

Attach patient label here. Physician Orders ADULT: Palliative Care Plan Initiate Orders Phase Care Sets/Protocols/PowerPlans Initiate Powerplan Phase T;N, Phase: Palliative Care Phase, When to Initiate: Palliative Care Phase Admission/Transfer/Discharge Patient Status Initial

More information

Agitation Excessive physical or mental restlessness. Increased activity that is generally not purposeful and associated with anxiety.

Agitation Excessive physical or mental restlessness. Increased activity that is generally not purposeful and associated with anxiety. October 2012 4 Agitation Excessive physical or mental restlessness. Increased activity that is generally not purposeful and associated with anxiety. Depending on appropriateness, evaluate for reversible

More information

Symptom Control in the Community Setting. Dr Andrew Tysoe-Calnon

Symptom Control in the Community Setting. Dr Andrew Tysoe-Calnon Symptom Control in the Community Setting Dr Andrew Tysoe-Calnon Lead Consultant t Common symptoms Pain Agitation Shortness of breath Nausea and vomiting Intestinal obstruction Confusion Pain Occurs in

More information

Advanced Symptom Management

Advanced Symptom Management Advanced Symptom Management Janet Bull, MD, FAAHPM Four Seasons Symptom Management o Objectives Define symptom clusters and the role of cytokines Identify different clusters and treatment options Describe

More information

Delirium and Dementia

Delirium and Dementia Delirium and Dementia Elder Friendly Care in Acute Care Seniors Health Strategic Clinical Network Acute Care Stress Blender Poor Poor sleep At-Risk Older Adult TREAT CAUSE immediately & aggressively. Increased

More information

Lab:2 Drugs acting on Gastrointestinal tract

Lab:2 Drugs acting on Gastrointestinal tract Lab:2 Drugs acting on Gastrointestinal tract Drugs that used to treat three common medical conditions involving the gastrointestinal tract: peptic ulcers and gastroesophageal reflux disease (GERD), chemotherapy-induced

More information

Symptom Management Challenges at End-of-Life

Symptom Management Challenges at End-of-Life Symptom Management Challenges at End-of-Life Amanda Lovell, PharmD, BCGP Clinical Pharmacist- Inpatient Units Optum Hospice Pharmacy Services February 15, 2018 Hospice Pharmacy Services Objectives Identify

More information

Palliative Medicine Overview. Francine Arneson, MD Palliative Medicine

Palliative Medicine Overview. Francine Arneson, MD Palliative Medicine Palliative Medicine Overview Francine Arneson, MD Palliative Medicine Palliative Medicine: Definition Palliative care: An approach that improves the quality of life of patients and their families facing

More information

Worshipping at the Porcelain Altar: Nausea and Vomiting

Worshipping at the Porcelain Altar: Nausea and Vomiting Worshipping at the Porcelain Altar: Nausea and Vomiting EDUARDO GODOY, MD FAMILY MEDICINE, SOUTH BAY MEDICAL CENTER TORRANCE MOB Financial Disclosures: I have no financial ties other than those owed: to

More information

CYCLIC VOMITING SYNDROME. C. Prakash Gyawali, MD Professor of Medicine Washington University in St. Louis

CYCLIC VOMITING SYNDROME. C. Prakash Gyawali, MD Professor of Medicine Washington University in St. Louis CYCLIC VOMITING SYNDROME C. Prakash Gyawali, MD Professor of Medicine Washington University in St. Louis Case 26 year old male Symptoms began at age 19 yr 5-6 day episodes of recurrent, severe vomiting

More information

Palliative Medicine in Critical Care Not Just Hospice. Robin. Truth or Myth 6/11/2015. Francine Arneson, MD Palliative Medicine

Palliative Medicine in Critical Care Not Just Hospice. Robin. Truth or Myth 6/11/2015. Francine Arneson, MD Palliative Medicine Palliative Medicine in Critical Care Not Just Hospice Francine Arneson, MD Palliative Medicine Robin 45 year old female married, husband in Afghanistan. 4 children ages 17-24. Mother has been providing

More information

If we are going to treat this, of course it's like most things, we want to treat the underlying cause as well as the effect.

If we are going to treat this, of course it's like most things, we want to treat the underlying cause as well as the effect. Systemic Management of Nausea: Antiemetics Bruce Flint O.D. Antiemetics: This is for controlling nausea and vomiting. These are multiple conditions that's causing this. It's kind of common. I'm sure all

More information

Drug Therapy Guidelines

Drug Therapy Guidelines Drug Therapy Guidelines Applicable Medical Benefit Effective: 6/15/18 Pharmacy- Formulary 1 x Next Review: 6/19 Pharmacy- Formulary 2 x Date of Origin: 4/99 Antiemetic Agents: Zofran /ODT (ondansetron/ondansetron

More information

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT A collaboration between: St. Rocco s Hospice, Bridgewater Community Healthcare NHS Trust, NHS Warrington Clinical Commissioning Group,

More information

Palliative Prescribing - Pain

Palliative Prescribing - Pain Palliative Prescribing - Pain LAURA BARNFIELD 21/2/17 Aims To understand the classes of painkillers available in palliative care To gain confidence in counselling regarding opiates To gain confidence prescribing

More information

Clinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Zuplenz) Reference Number: CP.PMN.45 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Antiemetics in chemotherapy

Antiemetics in chemotherapy Antiemetics in chemotherapy Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission Date

More information

Symptom Management for Patients Near End of Life

Symptom Management for Patients Near End of Life Symptom Management for Patients Near the End of Life Ritchell R. Dignam, MD Medical Director Vitas Healthcare 856-778-0222 Objectives Review the etiology and pathophysiology of common non-pain symptoms

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Kytril, Sancuso, Sustol) Reference Number: CP.PMN.74 Effective Date: 11.01.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important

More information

Management of Nausea and Vomiting

Management of Nausea and Vomiting June 01, 2015 By Rudolph M. Navari, MD, PhD, FACP [1] Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most

More information

Psychology of Pain DR. ARNEL BANAGA SALGADO,

Psychology of Pain DR. ARNEL BANAGA SALGADO, Psychology of Pain DR. ARNEL BANAGA SALGADO, Doctor of Psychology (USA) FPM (Ph.D.) Psychology (India) Doctor of Education (Phl) Master of Arts in Nursing (Phl) Master of Arts in Teaching Psychology (PNU)

More information

Care in the Last Days of Life

Care in the Last Days of Life Care in the Last Days of Life Introduction This guideline is an aid to clinical decision making and good practice in person-centred care for patients who are deteriorating and at risk of dying. The patient

More information

Controlling nausea and vomiting: anti-emetic therapy advice

Controlling nausea and vomiting: anti-emetic therapy advice Controlling nausea and vomiting: anti-emetic therapy advice Chemotherapy A guide for patients and carers Contents Treatments that may cause nausea and vomiting... 2 Physical reasons that may cause nausea

More information

Medications used for symptom control in palliative care

Medications used for symptom control in palliative care Learning Objectives used for symptom control in palliative care Luis Viana, R. Ph., M.Ed., CGP 1. For common symptoms experienced by the person managed with palliative care: Recognize the symptom to be

More information

Propulsion and mixing of food in the alimentary tract Chapter 63

Propulsion and mixing of food in the alimentary tract Chapter 63 Propulsion and mixing of food in the alimentary tract Chapter 63 Types of GI movements: Propulsive movement-peristalsis Propulsion: controlled movement of ingested foods, liquids, GI secretions, and sloughed

More information

Constipation An Overview. Definition Physiology of GI tract Etiology Assessment Treatment

Constipation An Overview. Definition Physiology of GI tract Etiology Assessment Treatment CONSTIPATION Constipation An Overview Definition Physiology of GI tract Etiology Assessment Treatment Definition Constipation = the infrequent passage of hard feces Definition of Infrequent The meaning

More information

Acute GI effects of radiotherapy

Acute GI effects of radiotherapy Acute GI effects of radiotherapy Dr Alex Stewart Hon Senior Lecturer, University of Surrey Clinical Director, St Luke s Cancer Centre, University of Surrey, Guildford Learning Objectives Acute Radiotherapy

More information

Supporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety

Supporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety Agitation & Anxiety (Exclude or treat REVERSIBLE causes*) Patient is anxious / frightened, but lucid Patient is confused, agitated and / or hallucinating MIDAZOLAM 2.5-5mg s/c (Max total 24 hour dose of

More information

MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life

MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life The following pages are guidelines for the management of common symptoms for a person thought to be

More information

PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE

PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE Reference: DCM029 Version: 1.1 This version issued: 07/06/18 Result of last review: Minor changes Date approved by owner (if applicable): N/A

More information

Supportive Care. End of Life Phase

Supportive Care. End of Life Phase Supportive Care End of Life Phase Guidelines for Health Care Professionals In the care of patients with established renal failure who are in the last days of life References: Chambers E J (2004) End of

More information

Using syringe pumps in palliative care

Using syringe pumps in palliative care Using syringe pumps in palliative care Facilitator: Barbara Stone RN Ground rules Medication matching game Learning outcomes To identify the indications for using a syringe pump To discuss the general

More information

DOMPERIDONE BNF 4.6. Domperidone is a dopamine type 2-receptor antagonist. It is structurally related to the

DOMPERIDONE BNF 4.6. Domperidone is a dopamine type 2-receptor antagonist. It is structurally related to the DOMPERIDONE BNF 4.6 Class: Prokinetic anti-emetic. Indications: Nausea and vomiting, dysmotility dyspepsia, gastro-oesophageal reflux. Pharmacology Domperidone is a dopamine type 2-receptor antagonist.

More information

Review Article Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting

Review Article Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 595894, 6 pages http://dx.doi.org/10.1155/2015/595894 Review Article Treatment of Breakthrough and Refractory Chemotherapy-Induced

More information

Clatterbridge Centre for Oncology

Clatterbridge Centre for Oncology Clatterbridge Centre for Oncology CONTENTS 1. Why and when to use a syringe driver 2. Siting the syringe driver 3. Mixing and measuring 4. Setting up the syringe driver 5. Drug information 6. Common problems

More information

Symptom Management Pocket Guides: DELIRIUM

Symptom Management Pocket Guides: DELIRIUM Symptom Management Pocket Guides: DELIRIUM August 2010 DELIRIUM Page Considerations. 1 Assessment 2 Diagnosis. 3 Non-Pharmacological treatment 3 Pharmacological treatment. 5 Mild Delirium... 6 Moderate

More information

Drug Class Review on Newer Antiemetics

Drug Class Review on Newer Antiemetics Drug Class Review on Newer Antiemetics Final Report January 2006 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative

More information

PAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose

PAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose NON-OPIOID SHORT-ACTING LONG-ACTING **** O PAIN TREATMENT TABLES Analgesics NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose Tramadol 50 mg Ultram Every 4 hours 1-2 tabs,

More information

Why Patients Experience Nausea and Vomiting and What to Do About It

Why Patients Experience Nausea and Vomiting and What to Do About It Why Patients Experience Nausea and Vomiting and What to Do About It Rebecca Clark-Snow, RN, BSN, OCN The University of Kansas Cancer Center Westwood, Kansas Multiple Roles for Supportive Care in Cancer

More information

Supportive Care for Patients with Cancer

Supportive Care for Patients with Cancer 3:15pm - 4:15pm: Breakout 4 - Oncology Option A: Supportive Care for Patients with Cancer ACPE UAN 0107-0000-10-021-L01-P 0.1 CEU/1.0 Hr. Activity Type: Application-Based Program Objectives for Pharmacists:

More information

Page 1 of 6 PATIENT PRESENTATION PROPHYLAXIS. No risk factors from the categories

Page 1 of 6 PATIENT PRESENTATION PROPHYLAXIS. No risk factors from the categories Page 1 of 6 PATIENT PRESENTATION PROPHYLAXIS risk factors from the categories listed below more than one drug prophylaxis (see Appendix A for antiemetic choices) Patient scheduled for surgery Assess patient

More information

Copy right protected Page 1

Copy right protected Page 1 DRUGS USED IN ULCERS AND GIT DISORDERS A peptic ulcer, also known as PUD or peptic ulcer disease is an ulcer of an area of the gastrointestinal tract that is usually acidic and thus extremely painful.

More information

Overview of Essentials of Pain Management. Updated 11/2016

Overview of Essentials of Pain Management. Updated 11/2016 0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.

More information

VOMITING. Tan Lay Zye

VOMITING. Tan Lay Zye VOMITING Tan Lay Zye Vomiting is a common symptom. It is a complex reflex behavioural response involving forceful expulsion of the stomach contents through oral cavity. Contents Emetic reflex Causes of

More information

Conflicts of Interest. Review of Antiemetic Guidelines. Learning Objectives. What is Emesis Anyways? Pharmacy Technician Learning Objectives

Conflicts of Interest. Review of Antiemetic Guidelines. Learning Objectives. What is Emesis Anyways? Pharmacy Technician Learning Objectives Conflicts of Interest No financial relationships to disclose Review of Antiemetic Guidelines Matthew Fox, PharmD, BCPS, BCOP Clinical Oncology Pharmacist Baptist MD Anderson Jacksonville, Florida October

More information

Anticipatory Medications for End of Life Patients. Doses must be proportional to the current analgesic medication YES NO YES NO

Anticipatory Medications for End of Life Patients. Doses must be proportional to the current analgesic medication YES NO YES NO Anticipatory Medications for End of Life Patients oses must be proportional to the current analgesic medication Please refer ALL patients on Methadone or Ketamine to palliative care team for advice. Patients

More information

7/13/16. Pharmaceuticals that alter GI motility. Financial disclosures. Common pharmaceuticals that alter GI Motility (an incomplete list) None

7/13/16. Pharmaceuticals that alter GI motility. Financial disclosures. Common pharmaceuticals that alter GI Motility (an incomplete list) None Pharmaceuticals that alter GI motility Megan Taylor, ND AANP 2016 Motility Bootcamp Financial disclosures None Common pharmaceuticals that alter GI Motility (an incomplete list) Analgesics Opioids NSAIDs

More information

Chemotherapy Induced Nausea and Vomiting

Chemotherapy Induced Nausea and Vomiting Chemotherapy Induced Nausea and Vomiting Aminah Jatoi, M.D. Professor of Oncology Mayo Clinic Rochester, Minnesota April 27, 2017 clinical and biologic fundamentals of chemotherapy induced nausea and vomiting

More information